It's possible LW is required to help structure and transact a complex deal with a equity position that is beyond the expertise of IPIX management. We can hope.
Make sure you have the shares you want to be holding come deal time.
Also from the 10-k- We have begun to strategically partner with other pharmaceutical companies through licensing agreements.
Perhaps the wording "have begun to strategically partner with other pharmaceutical companies" is the reason LW was engaged which is to help IPIX maximize the best possible match out of these other pharmaceutical companies.
Good post. After reading the IPIX PR's, blogs and Web site, my inference is IPIX has had expert help behind the scenes to move it to a place where a deal is fair to all parties. Locust Walk is in the business to structure such a deal. My guess is we could be receiving news of more interest after the BDD study of oral Brilacidin for IBD.
I am looking forward to seeing the what develops and my bet is the longs are going to be very happy.
Leo said that he will provide more clarity in the coming weeks.
“A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.”
Leo's riddle is still mainly unanswered. I did not see any hints in the 10 K, but the Locust Walk PR did have a few statement which points to a more aggressive plan to develop partnerships. I expect more news in the upcoming months.
"...we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
From the Locust Walk web site, an example of a complex partnership:
" October 7, 2010: SGI and JCVI announce formation of new company, SGVI, to develop next generation vaccines SGVI announces three-year collaboration with Novartis on the development of influenza vaccines using synthetic genomics technology. The agreement, supported by an award from the U.S. Biomedical Advanced Research and Development Authority (BARDA), could ultimately lead to a more effective response to seasonal and pandemic flu outbreaks.
My guess is IPIX has several suitors, domestic and international, who are proposing a variety of offers leading IPIX to hire a third party to structure the best deal and facilitate the closing of a deal. A deal which almost certainly will include Brilacidin for Inflammatory Bowel disease.
From the 9/10/2019 PR
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticalsstated,"If oral Brilacidin performs in UC like we believe it can, we should find ourselves in a strong negotiating position toward securing additional licensing agreements in a market that runs into the tens of billions of dollars.”
News 
Market Data 
Discover 
